Risk of severe breakthrough COVID-19 infection is higher for people with HIV with moderately low CD4 cell counts johnshopkinssph jamanetworkopen
Keri N. Althoff, PhD, MPH, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Rm E7142, Baltimore, MD 20295 .Ms Humes and Dr Althoff had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.Acquisition, analysis, or interpretation of data:
Lang, Humes, Coburn, Horberg, Watson, Jefferson, Park, Gordon, Akgün, Justice, Napravnik, Edwards, Browne, Agil, Silverberg, Skarbinski, Leyden, Stewart, Hogan, Gebo, Marconi, Althoff.Critical revision of the manuscript for important intellectual content: Lang, Humes, Coburn, Horberg, Watson, Jefferson, Park, Gordon, Akgün, Justice, Napravnik, Edwards, Browne, Agil, Silverberg, Skarbinski, Leyden, Stewart, Hogan, Gebo, Marconi, Williams, Althoff.Obtained funding:Fathi, Park, Gordon, Akgün, Justice, Napravnik, Edwards, Browne, Agil, Skarbinski, Leyden, Stewart, Hogan, Gebo.Dr Lang reported receiving grants from Canadian Institutes of Health Research , Alberta Innovates, and the University of Calgary paid to their institution.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
What is the association of masking behavior with SARS-CoV-2 infection?What is the association of masking behavior with SARS-CoV-2 infection? GWtweets SARSCoV2 COVID19 Masking Mask FaceMasks
Lire la suite »
The prevalence of COVID-19 vaccine hesitancy among the sub-Saharan adolescent populationThe prevalence of COVID-19 vaccine hesitancy among the sub-Saharan adolescent population PLOSGPH GeorgeMasonU UniIbadan Harvard COVID19 coronavirus covid vaccine
Lire la suite »
Molnupiravir and nirmatrelvir-ritonavir treatments are effective in reducing mortality among high-risk COVID-19 patientsMolnupiravir and nirmatrelvir-ritonavir treatments are effective in reducing mortality among high-risk COVID-19 patients HKUniversity COVID19 SARSCoV2 Mortality Molnupiravir NirmatrelvirRitonavir
Lire la suite »
Estimating the all-cause excess mortalities due to COVID-19In a new study, researchers estimated all-cause excess death rates due to the coronavirus disease 2019 (COVID-19) pandemic.
Lire la suite »